Fast Track Designation Explained: Complete FDA Guide for Drug Sponsors

Fast track designation is an FDA expedited program designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need. Established by the FDA Modernization Act of 1997 (FDAMA), fast track designation provides sponsors with more frequent FDA communication, eligibility for rolling review, and potential access to accelerated approval and priority review.

For pharmaceutical and biotech companies developing therapies for cancer, rare diseases, infectious diseases, or other serious conditions, fast track designation can significantly reduce time to market while ensuring rigorous safety and efficacy standards are maintained.

In this guide, you will learn:

• What qualifies a drug for FDA fast track designation and the eligibility criteria
• The specific benefits of fast track status including rolling review
• How fast track compares to breakthrough therapy, accelerated approval, and priority review
• The fast track designation application process and 60-day FDA response timeline
• Strategic considerations for drug development programs

What Is Fast Track Designation? Understanding FDA's Expedited Program

Fast track designation is one of four FDA expedited programs established to speed the development and review of drugs addressing serious conditions with unmet medical needs. Congress created the fast track program through the FDA Modernization Act of 1997 to encourage drug development for diseases without adequate treatment options.

Key characteristics of fast track designation:

• Applies to drugs and biologics intended to treat serious or life-threatening conditions
• Requires the drug to demonstrate potential to address an unmet medical need
• Provides more frequent meetings and communications with FDA
• Makes drugs eligible for rolling review of the marketing application

The fast track program represents FDA's commitment to getting promising therapies to patients faster. Unlike breakthrough therapy designation, which requires demonstrated clinical superiority, fast track designation focuses on whether the drug addresses an unmet medical need for a serious condition.

FDA Fast Track: How the Program Works

The FDA fast track program operates through both the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER), depending on the product type. Understanding how the program functions helps sponsors maximize its benefits.

Fast Track Program Structure

Serious Condition Definition

For fast track purposes, FDA defines a "serious condition" as a disease or condition associated with morbidity that has substantial impact on day-to-day functioning. Determining seriousness is a matter of judgment, but generally includes conditions that are:

1. Life-threatening - Diseases where death is possible or likely
2. Irreversibly debilitating - Conditions causing permanent harm
3. Significantly impairing - Diseases substantially affecting quality of life
4. Requiring hospitalization - Conditions needing inpatient treatment

Examples of serious conditions include cancer, HIV/AIDS, Alzheimer's disease, heart failure, rare genetic disorders, and serious infectious diseases.

Unmet Medical Need Definition

An unmet medical need exists when no therapy exists or available therapy is inadequate. FDA considers a medical need unmet if:

Fast Track FDA: Eligibility Criteria and Requirements

To qualify for fast track FDA designation, a drug must meet two primary criteria established by statute and clarified in FDA guidance.

Criterion 1: Intended to Treat a Serious Condition

The drug must be intended to treat a serious or life-threatening disease or condition. FDA evaluates seriousness based on:

Criterion 2: Potential to Address Unmet Medical Need

The drug must demonstrate potential to address an unmet medical need for the serious condition. This can be shown through:

Evidence Types for Unmet Medical Need:

“

Key Point: Unlike breakthrough therapy designation, fast track designation does not require demonstration of substantial improvement over existing therapies. The standard is "potential to address" unmet need, which is a lower evidentiary threshold.

What Does NOT Qualify

Fast track designation is not appropriate for:

• Drugs intended only for cosmetic purposes
• Products for conditions that are not serious
• Me-too drugs that offer no potential benefit over existing therapies
• Products where there is no unmet medical need

Fast Track Drug Approval: Benefits and Advantages

Fast track drug approval designation provides sponsors with meaningful benefits throughout the drug development process. Understanding these advantages helps sponsors maximize the value of the designation.

Benefit 1: More Frequent FDA Meetings

Fast track designation entitles sponsors to more frequent meetings and communication with FDA during the drug development process.

Benefit 2: Rolling Review Eligibility

Perhaps the most significant benefit, rolling review allows FDA to review completed sections of the NDA or BLA as they are submitted, rather than waiting for the entire application.

Rolling Review Impact:

Benefit 3: Accelerated Approval Eligibility

Fast track products may be eligible for accelerated approval based on surrogate endpoints or intermediate clinical endpoints that are reasonably likely to predict clinical benefit.

Benefit 4: Priority Review Eligibility

Fast track designation may support a request for priority review, which reduces the FDA review clock from 10 months to 6 months (or 8 months to 6 months for original BLAs).

Comprehensive Benefits Summary

Fast Track Status: Application Process and Timeline

Obtaining fast track status follows a structured process with a defined timeline. Understanding each step helps sponsors prepare effective requests.

Step 1: Determine Optimal Timing

Fast track designation can be requested at any time during drug development, from pre-IND through NDA/BLA submission. However, timing affects strategy:

Step 2: Prepare the Fast Track Request

A fast track designation request should include:

Step 3: Submit the Request

Submit the fast track request to FDA as an IND amendment or, if prior to IND, with the initial IND submission. The request should be clearly identified as a "Fast Track Designation Request."

Step 4: FDA Review and Response

FDA must respond to fast track designation requests within 60 calendar days of receipt. This timeline is established by statute in Section 506 of the FD&C Act.

Step 5: Post-Designation Activities

Once fast track designation is granted:

• Schedule Type B meetings to discuss development program
• Plan rolling review submission strategy
• Explore accelerated approval and priority review opportunities
• Maintain ongoing FDA communication throughout development

Fast Track vs. Breakthrough Therapy: Key Differences

Understanding the differences between fast track designation and breakthrough therapy designation helps sponsors select the appropriate expedited pathway.

Eligibility Comparison

Benefits Comparison

When to Pursue Fast Track vs. Breakthrough Therapy

“

Strategic Note: Products can receive both fast track and breakthrough therapy designations simultaneously. Many sponsors first obtain fast track designation and later apply for breakthrough therapy if clinical data demonstrate substantial improvement.

Fast Track Designation Statistics and Trends

Understanding the landscape of fast track designation helps sponsors benchmark their programs and set realistic expectations.

Fast Track Designation Trends

From FY 1998 through FY 2022, CDER received a cumulative total of 3,121 Fast Track designation requests, of which 2,090 were granted (approximately 67% grant rate). CDER receives approximately 250-320 fast track requests per year, with the grant rate generally trending upward over time. For the most current fiscal year data, consult the FDA CDER Fast Track Designation Requests page.

Fast Track Designations by Therapeutic Area

Oncology represents the largest share of fast track designations, followed by infectious diseases and rare diseases. These three areas collectively account for the majority of fast track grants, reflecting FDA's focus on conditions with the greatest unmet medical need.

Approval Outcomes for Fast Track Products

Fast track designated drugs frequently benefit from other expedited programs. In 2023, 25 of 55 CDER novel drug approvals (45%) had received Fast Track designation. In 2024, 66% of new drug approvals utilized one or more expedited programs. Fast track designation enables rolling review, which allows sponsors to submit completed sections of an NDA or BLA as they become available rather than waiting for the entire application.

All FDA Expedited Programs Compared

Fast track designation is one of four FDA expedited programs. Understanding all four helps sponsors optimize their regulatory strategy.

Complete Expedited Programs Comparison

Combining Expedited Programs

Products often receive multiple expedited designations. Common combinations include:

Common Fast Track Designation Challenges and Solutions

Challenge 1: Demonstrating Unmet Medical Need

Problem: Sponsors struggle to articulate unmet medical need when treatments exist for the condition.

Solution:

• Document limitations of current therapies with data
• Identify patient subpopulations without adequate options
• Quantify treatment failures, discontinuations, and adverse events
• Reference FDA guidance on unmet medical need interpretation

Challenge 2: Timing the Request

Problem: Uncertainty about optimal timing for fast track request.

Solution:

• Consider requesting during Phase 1 after initial safety data
• Earlier requests enable more FDA meeting opportunities
• Balance early filing with having adequate supporting data
• Pre-IND requests are possible but less common

Challenge 3: Demonstrating Serious Condition

Problem: Condition may not clearly meet "serious" definition.

Solution:

• Document impact on daily functioning
• Provide mortality and morbidity data
• Reference FDA precedent for similar conditions
• Include patient burden and quality of life impact

Challenge 4: Maintaining Designation

Problem: Concern about losing fast track status if development changes.

Solution:

• Fast track designation generally remains unless indication changes
• Communicate proactively with FDA about development pivots
• Request meeting to discuss any significant changes
• New indication may require new fast track request

Key Takeaways

Next Steps

Fast track designation can significantly accelerate your drug development timeline and improve FDA communication throughout the approval process. Understanding eligibility criteria, benefits, and application requirements helps sponsors maximize the value of this expedited program.

Organizations managing regulatory submissions benefit from automated validation tools that catch errors before gateway rejection. Assyro's AI-powered platform validates eCTD submissions against FDA, EMA, and Health Canada requirements, providing detailed error reports and remediation guidance before submission.

Sources